Changzhou Shenghui Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Taiwan Buster Pharmaceutical Company, which invested heavily in the mainland to acquire and relocate. The new factory was designed and built in accordance with the new version of GMP. It specializes in the research and development and production of new and upgraded external patches. It has raised the rubber patch to a new level in terms of process, equipment, inspection, allergy rate, application feel, appearance quality, and intrinsic efficacy, and has completely improved the rubber patch to a new level. It has changed the low-end image of traditional rubber plasters, such as being thick, hard, inferior and with high allergy rates. Its technical content is at the forefront of the world and has been affirmed and supported by relevant national departments. It is the drafting unit of the 2005 edition of the Pharmacopoeia General Principles for Plaster Preparations. In 2009, it undertook the work of the National Ministry of Science and Technology. The key technology research topic of external treatment with traditional Chinese medicine. The joint analgesic ointment, pepper rheumatism ointment, and musk bone strengthening ointment produced are not only favored by the majority of domestic patients, but also sold well in Taiwan and South Korea. They are widely praised by patients at home and abroad and are well-known. For --- a complete revolution in plasters. Shenghui Pharmaceutical has been committed to the research of various plasters since 1998, and has cooperated with Taiwan's Gaotang Traditional Chinese Medicine Clinic to study the effectiveness and safety of plasters. In 2014, it established Buster Medical Technology R&D in the field of medical devices. New medical equipment and consumables